News coverage about Covidien (NYSE:COV) has trended somewhat positive on Monday, Accern Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Covidien earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave media headlines about the healthcare company an impact score of 46.5157130829311 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Covidien (NYSE COV) remained flat at $$106.71 during trading hours on Monday. The stock has a market cap of $48,980.00, a PE ratio of 27.43 and a beta of 1.01. Covidien has a 1-year low of $65.97 and a 1-year high of $108.57.

WARNING: This report was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://theolympiareport.com/2017/12/25/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-covidien-cov-stock-price.html.

About Covidien

Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries.

Insider Buying and Selling by Quarter for Covidien (NYSE:COV)

Receive News & Ratings for Covidien Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covidien and related companies with Analyst Ratings Network's FREE daily email newsletter.